scholarly journals Correlation Between Symptom Severity and Health-Related Life Quality of a Population With Gastroesophageal Reflux Disease

2017 ◽  
Vol 10 (2) ◽  
pp. 78-83 ◽  
Author(s):  
Shou-Wu Lee ◽  
Teng-Yu Lee ◽  
Han-Chung Lien ◽  
Yen-Chun Peng ◽  
Hong-Jeh Yeh ◽  
...  
Keyword(s):  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Reflux Disease ◽  
Symptom Severity ◽  
Life Quality ◽  
Health Related

scholarly journals The Diagnostic Significance of Coapplying a Rabeprazole Test with the SF-36 for Gastroesophageal Reflux Disease

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Ying Chen ◽  
Feng Wang ◽  
Yuanxi Jiang ◽  
Chen Wang ◽  
Liwen Yao ◽  
...  
Keyword(s):  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Reflux Disease ◽  
Low Cost ◽  
Clinical Manifestations ◽  
Life Quality ◽  
Diagnostic Significance ◽  
Sf 36 ◽  
Before And After

Gastroesophageal reflux disease is a diversity disease that affects life quality of people in the world. Due to the complicated pathogenesis and variations in clinical manifestations, there is still no true gold standard for GERD diagnosis, and it is still difficult to diagnose this disease in some patients. The proton pump inhibitor’s diagnostic test (the PPI test) is noninvasive, of low cost, tied to treatment, and widely accepted. Our aim is to evaluate the diagnostic significance of coapplying a rabeprazole test with the SF-36 for GERD in this study. Our study shows that the SF-36 in combination with the rabeprazole test can screen GERD patients and increase the sensitivity and specificity of GERD diagnosis through reference to the change in SF-36 score before and after the treatment (65 in the trial).

scholarly journals Efficacy of combined therapy in patients with erosive gastroesophageal reflux disease

2021 ◽  
Vol 5 (6) ◽  
pp. 366-372
Author(s):  
I.V. Matoshina ◽  
◽  
M.A. Livzan ◽  
M.M. Fedorin ◽  
I.V. Lapteva ◽  
...  
Keyword(s):  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Reflux Esophagitis ◽  
Reflux Disease ◽  
Comparison Group ◽  
Combined Therapy ◽  
Life Quality ◽  
Main Group ◽  
Esophageal Mucosa

Aim: to evaluate the efficacy and safety of combined therapy with a proton pump inhibitor (PPI) and an esophagoprotector to relieve the symptoms of reflux esophagitis, improve the life quality of patients and achieve faster and complete disease remission. Patients and Methods: a randomized study included 60 patients, including 33 men (mean age 40.96±13.44 years) and 27 women (mean age 48.29±12.69 years) with a duration of gastroesophageal reflux disease (GERD) of 21.85±15.48 months and C/D stage of reflux esophagitis. Depending on the prescribed treatment, the patients were divided into 2 groups of 30 subjects. Patients of the main group received complex therapy: PPI pantoprazole 40 mg once per day and esophagoprotector based on hyaluronic acid, chondroitin sulfate and poloxamer 407. In the comparison group, only pantoprazole was prescribed at the same dosage. The duration of the treatment course in both groups was 4 weeks. Before and after treatment, the presence and severity of complaints were assessed on the Likert scale, life quality according to the SF-36 questionnaire and endoscopic examination data. Results: after the end of the therapy course, a statistically significant decrease in the severity of epigastric burning, regurgitation, substernal pain, gaseous eructation, odynophagia and dysphagia was found both in the main group (in all cases p<0.05, Wilcoxon Matched Pairs Test) and the comparison group (in all cases p<0,05, Wilcoxon Matched Pairs Test). The use of combination therapy made it possible to achieve a more significant improvement in the life quality of patients in all indicators versus PPI monotherapy. In addition, 3 (10%) patients of the main group achieved endoscopic remission, while there were no such patients in the comparison group. The use of esophagoprotector in addition to PPI made it possible to reach the primary and secondary endpoints significantly more commonly versus during monotherapy. Conclusion: the obtained data indicate the high efficiency and safety of PPI therapy in combination with esophagoprotector for relieving the disease symptoms and improving the life quality of patients, faster and complete remission of reflux esophagitis by additional restoration of the esophageal mucosa resistance. Esophagoprotector as a component of complex therapy together with PPI allows achieving clinical and endoscopic disease remission in patients with erosive esophagitis in shorter terms. KEYWORDS: gastroesophageal reflux disease, esophageal mucosa resistance, esophagoprotection, proton pump inhibitor, quality of life. FOR CITATION: Matoshina I.V., Livzan M.A., Fedorin M.M., Lapteva I.V. Efficacy of combined therapy in patients with erosive gastroesophageal reflux disease. Russian Medical Inquiry. 2021;5(6):366–372 (in Russ.). DOI: 10.32364/2587-6821-2021-5-6-366-372.

scholarly journals LIFE QUALITY OF FIREFIGHTERS OF THE CHORNOBYL NUCLEAR POWER PLAND DISASTER WITH COMORBIDITY OF ESSENTIAL HYPERTENSION AND GASTROESOPHAGEAL REFLUX DISEASE

2019 ◽  
Vol 19 (3) ◽  
pp. 79-82
Author(s):  
V. P. Synelnik ◽  
N. A. Tkachenko ◽  
A. S. Suprun
Keyword(s):  
Quality Of Life ◽  
Essential Hypertension ◽  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Reflux Disease ◽  
Standard Therapy ◽  
Nuclear Power ◽  
Life Quality ◽  
Role Functioning

This study was aimed at assessing the quality of life of 52 former fire-fighters of the Chornobyl nuclear power plant disaster with comorbidity of essential hypertension and gastroesophageal reflux disease. The subjects were divided into two groups similar by the sex and age (I group included 26 individuals with essential hypertension and II group included 26 individuals with comorbidity of essential hypertension and gastroesophageal reflux disease), their average age was 58,5±0,8 years. All patients received standard therapy (in accordance with the nosological form) added by the preparation Actovegin "Takeda Austria GmbH" in a dose of 200 mg once a day. The model, which underlies the designing of scales and total measurements of the SF-36 questionnaire, has three levels: 36 questions, 8 scales, formed by 2-10 questions; 2 total measurements, which are combined into scales. After calculating each indicator for separate scale, it was necessary to calculate the value of general indicators for the physical component and the psychological component of health taking into account the Z-value. In addition, when assessing the quality of life, three levels of assessment were conditionally identified: the minimum level ranged from 0 to 40 scores, satisfactory level – from 41 to 70 scores and the optimal ranged from 61 to 100 scores. The patients of the first group when having completed the therapy demonstrated statistically significantly improved indicators from 61.1 (0-100) scores to 71, 3 (0-100) (p ≤ 0.05) that consequently means the restrictions in role functioning due to physical condition (PF) decreased, overall health (OH) improved (scores increased from 42.7 (35-47) to 52.1 (47-60)) as well as the role functioning due to emotional state (ER) from 67.9 (0-100) to 76.5 (0-100) points. The second group when having completed the standard therapy added with Actovegin demonstrated statistically significantly improved indicators for most of the scales, and as a result, the subjective assessment of their quality of life was improved (p ≤ 0.05). Thus, the study has shown including Actovegin into standard therapy significantly improves most of the life quality parameters in both groups of the former fire-fighters of the Chornobyl nuclear power plant disaster. But, it should be noted that the indicators of pain scales and the state of overall health as parameters of life quality for the patients with comorbidy of hypertension and gastroesophageal reflux disease were fount at a minimum level compared with the patients having essential hypertension that indicates more significant restrictions in some fields of daily life activity for patients with comorbid pathology.

Sign in / Sign up

Export Citation Format

Share Document